VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Trading Up 3.4 %

Shares of NASDAQ:VBIV opened at $0.63 on Thursday. VBI Vaccines has a one year low of $0.45 and a one year high of $3.53. The company has a 50 day moving average of $0.61 and a 200-day moving average of $0.61.

Institutional Investors Weigh In On VBI Vaccines

Institutional investors have recently modified their holdings of the business. Engineers Gate Manager LP acquired a new stake in shares of VBI Vaccines during the 1st quarter worth approximately $26,000. Invesco Ltd. boosted its stake in VBI Vaccines by 24.8% during the 1st quarter. Invesco Ltd. now owns 479,765 shares of the biopharmaceutical company’s stock worth $797,000 after acquiring an additional 95,408 shares during the last quarter. UBS Group AG boosted its stake in VBI Vaccines by 45.5% during the 1st quarter. UBS Group AG now owns 1,032,103 shares of the biopharmaceutical company’s stock worth $1,714,000 after acquiring an additional 322,957 shares during the last quarter. Renaissance Technologies LLC bought a new position in VBI Vaccines during the 1st quarter worth approximately $286,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in VBI Vaccines by 2.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,644,720 shares of the biopharmaceutical company’s stock worth $2,731,000 after acquiring an additional 43,567 shares during the last quarter. Institutional investors and hedge funds own 12.26% of the company’s stock.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.